GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (STU:137) » Definitions » Shiller PE Ratio

Aldeyra Therapeutics (STU:137) Shiller PE Ratio : (As of Jun. 04, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aldeyra Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aldeyra Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Aldeyra Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics Shiller PE Ratio Chart

Aldeyra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aldeyra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aldeyra Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Aldeyra Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's Shiller PE Ratio falls into.



Aldeyra Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aldeyra Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Aldeyra Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.129/131.7762*131.7762
=-0.129

Current CPI (Mar. 2024) = 131.7762.

Aldeyra Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -1.148 100.560 -1.504
201409 -0.279 100.428 -0.366
201412 -0.243 99.070 -0.323
201503 -0.296 99.621 -0.392
201506 -0.241 100.684 -0.315
201509 -0.312 100.392 -0.410
201512 -0.422 99.792 -0.557
201603 -0.458 100.470 -0.601
201606 -0.365 101.688 -0.473
201609 -0.339 101.861 -0.439
201612 -0.351 101.863 -0.454
201703 -0.346 102.862 -0.443
201706 -0.312 103.349 -0.398
201709 -0.268 104.136 -0.339
201712 -0.304 104.011 -0.385
201803 -0.349 105.290 -0.437
201806 -0.394 106.317 -0.488
201809 -0.446 106.507 -0.552
201812 -0.343 105.998 -0.426
201903 -0.513 107.251 -0.630
201906 -0.434 108.070 -0.529
201909 -0.627 108.329 -0.763
201912 -0.423 108.420 -0.514
202003 -0.308 108.902 -0.373
202006 -0.222 108.767 -0.269
202009 -0.195 109.815 -0.234
202012 -0.247 109.897 -0.296
202103 -0.210 111.754 -0.248
202106 -0.232 114.631 -0.267
202109 -0.230 115.734 -0.262
202112 -0.239 117.630 -0.268
202203 -0.263 121.301 -0.286
202206 -0.284 125.017 -0.299
202209 -0.253 125.227 -0.266
202212 -0.208 125.222 -0.219
202303 -0.252 127.348 -0.261
202306 -0.138 128.729 -0.141
202309 -0.131 129.860 -0.133
202312 -0.073 129.419 -0.074
202403 -0.129 131.776 -0.129

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aldeyra Therapeutics  (STU:137) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Aldeyra Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aldeyra Therapeutics (STU:137) Business Description

Traded in Other Exchanges
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Aldeyra Therapeutics (STU:137) Headlines

No Headlines